Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT00002508

Extragonadal Germ Cell Tumor Ovarian Cancer Testicular Germ Cell Tumor

COMPLETED PHASE1/PHASE2

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

NCT00002948

Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE1

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515

Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Head and Neck Cancer +8 more

COMPLETED PHASE2

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

NCT00005021

Lymphoma Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00006373

Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Three patients will be accrued at each of 5 dose levels. Dose escalation will only proceed if none of the additional 3 patients experience DLT. The highest dose level that generates DLT in 0/3 or 1/6 patients will be the maximum tolerated dose (MTD) or the doses recommended for subsequent studies. A total of 10 patients will be treated at the MTD to further assess the toxicity of the dosing regimen and its suitability for use in subsequent trials. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered. Treatment cycles will be repeated every 21 days. The protocol is also designed to enroll an additional 10 patients at the maximum tolerated dose to increase the confidence in the safety and suitability of the doses that are chosen for subsequent studies.

* Topotecan Day 1 and 8
* Pemetrexed Day 1

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer Endometrial Cancer Cervical Cancer Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pemetrexed

Intervention Type DRUG

topotecan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven advanced solid tumors
* Measurable or evaluable disease
* Age ≥ 18 years
* Karnofsky performance status ≥ 80% (ECOG 0 or 1)
* Adequate liver, bone marrow and kidney function

Exclusion Criteria

* More than 3 prior chemotherapy regimens in the metastatic setting
* Prior treatment with topotecan or pemetrexed
* Clinically significant third space fluid present at the time of treatment
* Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs
* Inability to take steroid premedications or vitamin supplementation
* The presence of active brain metastases
* Prior radiotherapy within 4 weeks prior to the first day of treatment
* Prior surgery within 3 weeks prior to the first day of treatment
* Prior chemotherapy within 3 weeks prior to the first day of treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No